FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders

FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders

Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase...

Full description

Bibliographic Details
Main Authors: Austin Lui, Jordan Vanleuven, David Perekopskiy, Dewey Liu, Desiree Xu, Omar Alzayat, Taiseer Elgokhy, Timothy Do, Meghan Gann, Ryan Martin, Da-Zhi Liu
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceuticals
Subjects:
aberrant cell cycle disease
cancers
neurological disorders
kinase inhibitors
Online Access:https://www.mdpi.com/1424-8247/15/12/1546

Internet

https://www.mdpi.com/1424-8247/15/12/1546

Similar Items